Evidence map›Paper›PMID 39882681›Full record

ReviewCurrent opinion in pediatrics2026

Updates in atypical hemolytic syndrome.

Keri Drake, Jyothsna Gattineni

Abstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Keri DrakeDivision of Pediatric Nephrology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jyothsna Gattineni

Funding

Consequences of Elevated Fibroblast Growth Factor 23 in the Presence and Absence of Kidney DiseaseR01DK118021 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI GATTINENI, JYOTHSNA · 2018 to 2022
$1.6M
Wilms tumor 1 (Wt1) mutation reveals mechanisms of cell lineage crosstalk in the developing kidneyK08DK131258 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI DRAKE, KERI ANNE · 2022 to 2024
$502k
NIDDK NIH HHS K08 DK131258NIDDK NIH HHS R01 DK118021
6 · The paper itself

Abstract

purpose of reviewThis review aims to summarize how scientific advances in complement biology have not only improved the diagnosis and management of aHUS but also continue to offer insights into the pathophysiology of complement-mediated disease that may be leveraged for future therapeutic developments. RECENT

findingsUpdated information on the clinical and epidemiological features, pathophysiology, diagnosis, management, and potential for future therapeutic advancements in the treatment of aHUS are reviewed. SUMMARY: aHUS is a rare but potentially life-threatening disease that requires prompt diagnosis and treatment as well as long-term management via a multidisciplinary team providing coordination of primary and specialty care as well as outreach and education for children and families affected by this life-long disease.

Indexed as

Atypical Hemolytic Uremic SyndromeChildHumansatypical hemolytic uremic syndromecomplement dysregulationcomplement inhibitorscomplement therapeuticsplasmapheresis

Identifiers

PMID39882681
PMCPMC13412028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.